← The Wire·Earnings··2 outlets

Amgen, Novartis decline on disappointing clinical trial results; details not disclosed

Disappointing clinical-trial results are weighing on Novartis, Amgen and the Dow in Tuesday trading. With no trial readout details disclosed in the report, the immediate setup is a sentiment hit whose effect on Amgen’s earnings outlook remains unquantified.

STOCK PHOTO · FABIO RICCOBONO

The story

Disappointing clinical-trial results were dragging Novartis, Amgen and the Dow lower Tuesday. The trial, its endpoint, the affected drug and the size of the market reaction remain unclear, establishing a broad negative read on pharmaceutical shares without showing how the result changes Amgen's operating outlook.

Amgen's latest company figures are for fiscal 2025: revenue was $36.8 billion, up 10.0% year over year, with a 21.0% net margin and diluted EPS of $14.23. Those figures describe the company's overall financial base, but they do not establish the contribution of the clinical program or quantify any potential revenue loss.

For AMGN, the mechanism would run through the affected drug's development prospects, potential launch revenue and research spending; none of those links can be sized from available information. Novartis is also named, but it remains unclear whether the same trial affected both companies or whether separate clinical setbacks were involved.

The central uncertainty is material: the trial outcome, the companies' statements, and management's response are not yet known. Until the drug, indication and endpoint are identified, the negative read is clear but a company-specific estimate of changed earnings cannot be made.

The next useful evidence would be an issuer statement or fuller trial disclosure identifying the program, followed by any regulatory update or company earnings discussion that quantifies its financial importance.

Our read · Tue, Sep 8

The headline is negative for AMGN and NVS, but the missing trial details keep the read at sentiment damage rather than a quantified earnings reset.

Why. The immediate consequence is a sentiment hit without enough disclosure to connect it to AMGN's $36.8B revenue base or $14.23 diluted EPS. The company's 10.0% revenue growth and 21.0% net margin provide operating context, but the program is unidentified and a forecast change cannot be established.

Both cases

The case it holdsAMGN’s FY2025 revenue grew 10.0% to $36.8B with a 21.0% net margin.
The case it breaksThe unnamed clinical setback could damage a development asset or future launch opportunity, but Yahoo Finance gives no drug, endpoint or financial exposure to quantify that risk.

What could change this view: A fuller company or trial disclosure could show the result is immaterial to AMGN or identify a different company-specific exposure than the headline implies.

Amgen stock page →
Your side is graded privately against closes after 10 trading days. Research, not advice.

Who reported it · 2

Keep reading

More on AMGN

Amgen and AstraZeneca report positive lung cancer trial results

Latest on the Wire

AMD shares fall 11% after Hunterbrook warns over China linksWalmart raises full-year outlook as e-commerce wins shoppersAnthropic IPO could become the largest in US history on ThursdayContinuing claims rise as Goldman sees Fed hikes in December and MarchPIF Tower in Riyadh reportedly damaged in second Houthi attackContinue on the Wire →

Top this week

Nvidia allies lobby board to bring back Jensen Huang as CEONvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangNvidia CEO Jensen Huang reportedly resigns as US-China tensions rise
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.

About this report

Reported by Yahoo Finance as Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday, . Who answers for this

2 reports from 1 publisher in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →

Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →